Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Endocr Relat Cancer. 2002 Sep;9(3):183-95.

The biology of neoadjuvant chemotherapy for breast cancer.

Author information

  • 1Academic Department of Biochemistry, Royal Marsden Hospital, Fulham Road, London SW3 6JJ, UK. scleator@icr.ac.uk

Abstract

Neoadjuvant/pre-surgical medical therapy of breast cancer provides a unique opportunity to derive biological information related to tumour response. Large clinical trials of neoadjuvant chemotherapy have established that pathological complete remission is an independent predictor of improved disease-free survival. Clinical response has been found to parallel substantial reductions in the proliferation of breast cancer cells. Increased apoptosis also occurs, but it is not closely associated with response. Numerous biological markers such as p53, bcl-2, oestrogen receptor (ER) and HER2 have been assessed for their possible role in chemoresistance/response, but the data are not clear at this stage. Continuing work using cDNA microarrays may yield new, more reliable indices of likely response and an improved insight into biological processes related to chemotherapeutic response.

PMID:
12237246
[PubMed - indexed for MEDLINE]
Free full text
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Icon for HighWire
    Loading ...
    Write to the Help Desk